国产齐拉西酮与维思通治疗精神分裂症的对照研究  

A controlled Study of Domestic Ziprasidone and Risperidone in the Treatment of Schizophrenia

作　　者：刘国雄[1] 阳琼[1] 薛士健[1] 蔡颖莲[1] 李爱凤[1] 

机构地区：[1]广州市精神病医院精神科,广东广州510370

出　　处：《国际医药卫生导报》2007年第7期48-51,共4页International Medicine and Health Guidance News

摘　　要：目的探讨国产齐拉西酮治疗精神分裂症的疗效和安全性。方法将71例精神分裂症住院患者随机分为齐拉西酮治疗组（5例）和维思通治疗组（36例），于治疗前和治疗第1、2、4、6w末采用阳性与阴性症状量表（PANSS）评定患者的疗效，以治疗中需处理的不良反应症状量表（TESS）评定患者的副反应。结果71例患者均完成6周观察。在治疗第6周末，齐拉西酮组有效率88．6％，显效率60．0％；维思通组有效率86．1％，显效率61．1％，两组患者疗效（x^2=0．180，P=0．981）方面的差异未达到统计学显著程度，但齐拉西酮对阴性症状的改善优于维思通。齐拉西酮组不良反应少、严重程度轻，很少引起锥体外系反应、体重增加。结论齐拉西酮是一种安全有效的抗精神病药，尤其有助于阴性症状的改善。Objective To explore the efficacy and safety of domestic ziprasidone and risperidone in treating hospitalized patients with schizophrenia. Methods 71 patients with schizophrenia were randomly divided into domestic ziprasidone group（n=35）and risperidone group（n=36）. The efficacy was assessed by the Positive and Negative Symptoms Scale（PANSS） and the safety was assessed by Treatment Emergent Symptoms Scale（TESS） before treatment and at the ends of week 1, 2, 4 and 6, respectively. Results All 71 cases were finished the 6-weeks observation. After 6 weeks treatment, the total scores of PANSS were significantly reduced from baseline in the two groups. The eficacy rate of ziprasidone Was 88.6%, in which 60.0% were improved markly. The eficacy rate of risperidone Was 86.6%, in which 61.1% were improved markly. There was similar effect between two groups. However, ziprasidone had a better result in negative symptoms. The patients treated with ziprasidone showed less and mild side effect and less weight gain and less extra pyramidal symptoms（EPS） than the patients treated with risperidone. Conclusion Domestic ziprasidone is effective and safe antipsychotics. Specifically in improving in negative symptoms.

关 键 词：精神分裂症 齐拉西酮 维思通 

分 类 号：R74[医药卫生—神经病学与精神病学]